HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.

AbstractPURPOSE:
Vascular endothelial growth factor signaling pathway plays a crucial role in angiogenesis and has become a promising target for cancer drug development. We aimed to quantify the overall efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer (NSCLC).
METHODS:
Electronic databases were searched for randomized controlled trials (RCTs) comparing angiogenesis inhibitors with non-angiogenesis inhibitors for NSCLC patients. The extracted data on objective response rates (ORRs), disease control rates (DCRs), progression-free survival (PFS) and overall survival (OS) were pooled. Common adverse events (AEs) were also studied.
RESULTS:
A total of 33 RCTs involving 17,396 patients were included. Compared with non-angiogenesis inhibitors, angiogenesis inhibitors resulted in significant improvement in PFS (HR, 0.81; 95 % CI 0.76-0.85; p < 0.001), OS (HR, 0.95; 95 % CI 0.92-0.98; p = 0.004), ORR (RR, 1.54; 95 % CI 1.37-1.73; p < 0.001) and DCR (RR, 1.18; 95 % CI 1.10-1.27; p < 0.001). The AEs associated with angiogenesis inhibitors were generally predictable and manageable.
CONCLUSION:
Angiogenesis inhibitors were superior to non-angiogenesis inhibitors in terms of ORR, DCR, PFS and OS in advanced NSCLC patients. Further studies are warranted to explore the predictive biomarkers to pick up those who may gain utmost benefit from anti-angiogenic therapy.
AuthorsShaodong Hong, Min Tan, Shouzheng Wang, Shengyuan Luo, Yue Chen, Li Zhang
JournalJournal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 141 Issue 5 Pg. 909-21 (May 2015) ISSN: 1432-1335 [Electronic] Germany
PMID25373315 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Indazoles
  • Indoles
  • Phenylurea Compounds
  • Piperidines
  • Pyrimidines
  • Pyrroles
  • Quinazolines
  • Sulfonamides
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • pazopanib
  • Sorafenib
  • ramucirumab
  • Receptors, Vascular Endothelial Growth Factor
  • cediranib
  • Sunitinib
  • vandetanib
Topics
  • Angiogenesis Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Bevacizumab
  • Carcinoma, Non-Small-Cell Lung (drug therapy, metabolism, pathology)
  • Disease-Free Survival
  • Hemorrhage (chemically induced)
  • Humans
  • Indazoles
  • Indoles (therapeutic use)
  • Lung Neoplasms (drug therapy, metabolism, pathology)
  • Niacinamide (analogs & derivatives, therapeutic use)
  • Odds Ratio
  • Phenylurea Compounds (therapeutic use)
  • Piperidines (therapeutic use)
  • Pyrimidines (therapeutic use)
  • Pyrroles (therapeutic use)
  • Quinazolines (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors, metabolism)
  • Signal Transduction (drug effects)
  • Sorafenib
  • Sulfonamides (therapeutic use)
  • Sunitinib
  • Thrombocytopenia (chemically induced)
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: